Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2
- PMID: 17931986
- DOI: 10.1016/j.bbapap.2007.08.017
Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2
Abstract
CK2 is a highly conserved protein serine/threonine kinase that is ubiquitously distributed in eukaryotes, constitutively active and has been implicated in multiple cellular functions, as well as in tumorigenesis and transformation. Elevated CK2 activity has been associated with the malignant transformation of several tissues and is associated with aggressive tumor behaviour. While the precise roles of CK2 in tumorigenesis remain incompletely understood, mounting evidence suggests a role for CK2 in the protection of cells from apoptosis via the regulation of tumor suppressor and oncogene activity. Consequently, CK2 has emerged as a potential therapeutic target, and strategies to inhibit CK2 have been ongoing in pre-clinical trials. This review will focus on published evidence highlighting the molecular mechanisms by which CK2 functions in the promotion of tumorigenesis, as well as review current strategies being used to inhibit CK2.
Similar articles
-
[Casein kinase 2, the versatile regulator of cell survival].Mol Biol (Mosk). 2012 May-Jun;46(3):423-33. Mol Biol (Mosk). 2012. PMID: 22888632 Review. Russian.
-
Casein Kinase II: an attractive target for anti-cancer drug design.Int J Biochem Cell Biol. 2010 Oct;42(10):1602-5. doi: 10.1016/j.biocel.2010.06.010. Epub 2010 Jun 15. Int J Biochem Cell Biol. 2010. PMID: 20558317 Review.
-
New protein kinase CK2 inhibitors: jumping out of the catalytic box.Chem Biol. 2009 Feb 27;16(2):112-20. doi: 10.1016/j.chembiol.2009.01.004. Chem Biol. 2009. PMID: 19246001 Review.
-
Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.Curr Pharm Des. 2017;23(1):95-107. doi: 10.2174/1381612822666161006154311. Curr Pharm Des. 2017. PMID: 27719640 Review.
-
Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.Biochim Biophys Acta. 2013 Jul;1834(7):1352-8. doi: 10.1016/j.bbapap.2013.02.006. Epub 2013 Feb 14. Biochim Biophys Acta. 2013. PMID: 23416530 Review.
Cited by
-
Serine/Threonine Protein Kinases as Attractive Targets for Anti-Cancer Drugs-An Innovative Approach to Ligand Tuning Using Combined Quantum Chemical Calculations, Molecular Docking, Molecular Dynamic Simulations, and Network-like Similarity Graphs.Molecules. 2024 Jul 5;29(13):3199. doi: 10.3390/molecules29133199. Molecules. 2024. PMID: 38999151 Free PMC article.
-
Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity.Haematologica. 2016 Nov;101(11):1368-1379. doi: 10.3324/haematol.2015.141143. Epub 2016 Jul 28. Haematologica. 2016. PMID: 27470599 Free PMC article.
-
Protein kinase CK2: a potential therapeutic target for diverse human diseases.Signal Transduct Target Ther. 2021 May 17;6(1):183. doi: 10.1038/s41392-021-00567-7. Signal Transduct Target Ther. 2021. PMID: 33994545 Free PMC article. Review.
-
The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells.Oncogenesis. 2019 Oct 22;8(11):61. doi: 10.1038/s41389-019-0171-x. Oncogenesis. 2019. PMID: 31641101 Free PMC article.
-
Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.CNS Neurosci Ther. 2022 Jul;28(7):1033-1044. doi: 10.1111/cns.13835. Epub 2022 Apr 14. CNS Neurosci Ther. 2022. PMID: 35419951 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
